For more than a decade Bethan has been living with a chronic refractory cough, the medical term for a condition with no obvious cause. It's a common complaint thought to affect one in ten of the ...

Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck & Co's rival drug gefapixant.

At the moment there are no approved therapies for suppressing refractory chronic cough, defined as lasting for eight weeks or more, which is estimated to affect somewhere between 5% and 10% of ...

Analyst Serge Belanger from Needham maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report) and keeping the price target at ...

Two trials of a new drug have shown that at low doses, it can ease the often distressing symptoms of chronic cough with minimal side effects. Principle researcher Jacky Smith, a Professor of ...

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) on January 10 and set a price ...